RecruitingPhase 1NCT05587205

Safety and Tolerability of EO2002

Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery

Sponsor

Asociación para Evitar la Ceguera en México

Enrollment

32 participants

Start Date

Aug 30, 2022

Study Type

INTERVENTIONAL

Conditions

Endothelial Cell Loss, Corneal Cataract

Summary

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called EO2002 and Sham injection for people with cataract and endothelial cell loss, corneal. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEO2002

Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

OTHERSham injection

Sham injection